BioCentury
ARTICLE | Top Story

Sanofi, UCB in deal for immune-mediated diseases

March 12, 2014 12:42 AM UTC

Sanofi (Euronext:SAN; NYSE:SNY) and UCB Group (Euronext:UCB) partnered to jointly discover and develop oral small molecules targeting undisclosed pathways to treat immune-mediated diseases. The partners will use an approach developed by UCB to identify modulators of the pathway, for which the partners said biologics "have proven highly efficacious." UCB said the partners expect to identify a lead preclinical compound "shortly." UCB is eligible to receive more than EUR 100 million ($139 million) from Sanofi in an undisclosed upfront and milestone payments. The partners will split costs and profits evenly. ...